SCHEMBL1363923

SCHEMBL1363923

CC(=O)c1cc(CC(=O)O)cs1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.69
NPSR1 Q6W5P4 1/20 0.69
POLB P06746 4/20 0.49
HPGD P15428 3/20 0.49
TP53 P04637 1/20 0.48
DAO P14920 2/20 0.43
RPS6KB2 Q9UBS0 1/20 0.42
HTT P42858 1/20 0.40
GSK3B P49841 1/20 0.40
AKR1B1 P15121 1/20 0.39
MMP12 P39900 1/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 2/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
KDM4E B2RXH2 2/20 0.37
RGS12 O14924 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8508372 0.84 DAO (0.59) MAPTNPSR1POLBHPGDDAO
SCHEMBL26118640 0.83 MAPT (0.67) MAPTNPSR1POLBHPGDTP53
SCHEMBL1613233 0.80 MAPT (0.74) MAPTNPSR1POLBHPGDTP53
SCHEMBL11636348 0.78 MAPT (0.71) MAPTNPSR1POLBHPGDTP53
SCHEMBL23189011 0.77 MAPT (0.79) MAPTNPSR1POLBHPGDTP53
SCHEMBL11922972 0.76 DAO (0.50) MAPTNPSR1POLBHPGDDAO
SCHEMBL27941751 0.76 MAPT (0.67) MAPTNPSR1POLBHPGDTP53
SCHEMBL27649500 0.76 MAPT (0.67) MAPTNPSR1POLBHPGDTP53
SCHEMBL13125587 0.76 MAPT (0.67) MAPTNPSR1POLBHPGDTP53
SCHEMBL11540493 0.75 KMT2A (0.53) MAPTNPSR1HPGDDAORPS6KB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
WO-2023183405-A2 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2023-09-28 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
US-8067409-B2 Protein kinase inhibitors ABBOTT LABORATORIES (US) 2011-11-29 US disclosed
EP-2222682-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2010-09-01 EP disclosed
US-20090253723-A1 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-10-08 US disclosed
WO-2009070516-A1 IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2009-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253723-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 MAPT 1359/4885NPSR1 4339/4885POLB 1211/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 MAPT 1464/4885NPSR1 1506/4885POLB 3148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.